Impact of Ocrelizumab Vs. Interferon Beta-1a In Delaying The Deterioration Of Patients' Daily Functions and Associated Costs In Relapsing-Remitting Multiple Sclerosis
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1933
https://www.valueinhealthjournal.com/article/S1098-3015(17)32267-2/fulltext
Title :
Impact of Ocrelizumab Vs. Interferon Beta-1a In Delaying The Deterioration Of Patients' Daily Functions and Associated Costs In Relapsing-Remitting Multiple Sclerosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32267-2&doi=10.1016/j.jval.2017.08.1933
First page :
A721
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1764